Calquence Haematology events, resources and support materials for HCPs and patients
Browse our selection of events, resources and support materials to aid in the initiation and maintenance of CALQUENCE therapy.
If you have any questions or need any further support, you can contact one of our team members here.
The MCL Exchange: New Horizons in MCL: Clinical Advances and Trials
Are you aware of a new 1L treatment option for eligible MCL patients? Hear from Dr Faye Sharpley, Dr David Lewis & Dr Matthew Wilson.
The CLL Exchange: Managing Cardiovascular Comorbidities and Complications in CLL
How do you manage cardiovascular complications in CLL patients? Learn more from Dr Faye Sharpley and Prof Charlotte Manisty.
The CLL Exchange: UK real-world evidence in CLL
Are you aware of UK real-world evidence in CLL? Hear from Dr Mark Raffety, Dr Dino Maw and Dr Faye Sharpley.
CLL National Summit 2025: Patient perspectives
Watch Cath, a CLL patient, who shares her perspectives on diagnosis, active monitoring, treatment, awareness and support in a video developed for the CLL National Summit 2025.
CLL National Summit 2025: The patient voice
Watch Philip, a CLL patient who shares his experience of diagnosis, active monitoring, treatment, awareness and support in a video developed for the CLL National Summit 2025.
UK EPIC Study: 3 year follow-up
A summary of the EPIC 3 year data - UK real-world evidence in CLL
UK Real-World Evidence Posters in CLL
Explore UK real-world evidence posters which focus on CALQUENCE (acalabrutinib) use in CLL.
CLL Exchange Bite-sized: Cardiac comorbidity decision making in 1L CLL
Join Dr Renata Walewska discussing what guides decision making for CLL patients with cardiac comorbidities.
CALQUENCE in CLL & MCL: Clinical Guide
A practical overview of licensed CALQUENCE use in CLL and MCL, including key efficacy, safety and dosing information relevant to each indication.
BSH Guidelines 2025 for the 1L Treatment of CLL
A summary of the BSH guidelines for the 1L treatment of CLL, and key efficacy and safety information for CALQUENCE across both fixed and continuous treatment options.
Calquence Continuous Treatment CLL Patient Information Booklet
Patient information booklet for eligible adult patients prescribed Calquence continuous treatment providing helpful information about CLL and Calquence therapy
CLL Exchange Bite-sized: Cardiac comorbidity decision making in 1L CLL
Join Dr Renata Walewska discussing what guides decision making for CLL patients with cardiac comorbidities.
CLL Exchange Bite-sized: Fixed-duration decision making in 1L CLL.
Join Dr Renata Walewska discussing how decision making is evolving when selecting a fixed-duration treatment option for 1L CLL.
AMPLIFY video: Fixed- duration CALQUENCE (acalabrutinib) combinations in previously-untreated CLL
International Expert Prof John Seymour presents AMPLIFY trial data evaluating the efficacy and safety of CALQUENCE (acalabrutinib) in combination with venetoclax, with or without obinutuzumab
BSH Guidelines 2025 for the 1L Treatment of CLL
A summary of the BSH guidelines for the 1L treatment of CLL, and key efficacy and safety information for CALQUENCE across both fixed and continuous treatment options.
AMPLIFY Clinical Trial Summary
A summary of the AMPLIFY trial - a fixed-duration combination in 1L CLL.
CALQUENCE in CLL & MCL: Clinical Guide
A practical overview of licensed CALQUENCE use in CLL and MCL, including key efficacy, safety and dosing information relevant to each indication.
Calquence + Venetoclax 1L CLL Patient Information Booklet
Patient information booklet for patients prescribed Calquence + Venetoclax for 1L CLL providing helpful information about CLL and Calquence therapy
Join our mailing list
and keep in touch
Want to stay up to date on CALQUENCE and receive the latest news and support materials?
Abbreviations:
CLL, chronic lymphocytic leukaemia; NICE, National Institute for Health and Care Excellence; R/R, relapsed/refractory; SMC, Scottish Medicines Consortium.
Adverse events should be reported
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.
September 2025 | GB-69434